## **Core Concept**
Relcovaptan is a selective **V1a vasopressin receptor antagonist**. Vasopressin receptors are part of the vasopressin/oxytocin family of G protein-coupled receptors, and they play significant roles in various physiological processes, including water homeostasis and vascular tone regulation.

## **Why the Correct Answer is Right**
Relcovaptan specifically targets the **V1a receptor**, which is one of the receptor subtypes for vasopressin. By antagonizing this receptor, relcovaptan can potentially influence conditions associated with excessive vasopressin activity, such as certain forms of heart failure or hyponatremia. Its mechanism involves blocking the action of vasopressin at the V1a receptor, which can lead to vasodilation and potentially beneficial effects in specific cardiovascular and fluid balance disorders.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Incorrect because without specific details on the mechanism or classification of the drug in option A, it's not possible to directly refute it, but given that relcovaptan is known to be a V1a antagonist, any option not corresponding to this classification would be incorrect.
- **Option B:** Incorrect for similar reasons as option A; it does not align with the known pharmacological profile of relcovaptan as a V1a vasopressin receptor antagonist.
- **Option C:** Incorrect as there's no provided information that would suggest relcovaptan acts through a different primary mechanism or classification that would align with option C.
- **Option D:** Although not directly provided, assuming it's not the correct classification of relcovaptan as a V1a vasopressin receptor antagonist, it would be incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **vasopressin receptor antagonists**, like relcovaptan, are explored for their potential in treating conditions like **hyponatremia** and certain types of **heart failure**, where modulation of vasopressin activity can have therapeutic benefits. Understanding the specific receptor subtypes and their antagonists can help in managing and treating various clinical conditions.

## **Correct Answer:** D. Relcovaptan is a selective V1a vasopressin receptor antagonist.